JOURNEY

📅 Upcoming

🕒 Recent(90d)

News

• New biotech Setara forms with $90M to take on Jazz’s bonus rare disease programs
  Setara Biosciences has formed around a handful of assets from Actio Biosciences, which was acquired by Jazz Pharmaceuticals earlier this year.
  biospace · 1d ago
• Jazz's $820M Actio buyout gives rise to Setara, armed with $90M series A
  Setara Biosciences, a privately held spinout formed following Jazz Pharmaceuticals' acquisition of Actio Biosciences in September, has raised $90 million in series A financing to advance its clinic…
  fiercebiotech · 2d ago
• Opinion: Freezing my eggs showed me just how anti-feminist the fertility industry can be
  “A few years ago, I froze my eggs — and the experience was anything but empowering,” writes physician Pooja Yerramilli.
  stat · 3d ago
• A virus that afflicts cows makes the jump to a human
  For the first time, a human has been infected with the Shamonda virus, according to French officials. The World Health Organization says broader transmission is unlikely.
  stat · 5d ago
• The 4 stages of women’s heart health: New framework for doctors and patients
  New guidance is intended to help girls and women — and their doctors — recognize four distinct phases in heart health.
  stat · 5d ago
• Opinion: It took me 13 years to be diagnosed with MS. Christina Applegate’s misdiagnosis doesn’t surprise me
  “I felt Christina Applegate’s disappointment as if it were my own — because not long ago, it was,” writes Lindsay Karp.
  stat · 8d ago
• Critical decisions that spurred these 40 Under 40 winners to success
  Securing financing that allowed an exit from academia, leaving ecology and evolutionary biology for biomedical engineering and shifting from business development to entrepreneurship are among key t…
  biospace · 10d ago
• AstraZeneca taps Oracle to help improve recruitment for clinical trials
  AstraZeneca has turned to data giant Oracle as the U.K.-based Big Pharma works on one of the eternal problems of drug development—improving patient recruitment.
  fiercebiotech · 12d ago
• Should amylin have been obesity therapeutics’ primary target from the start?
  While GLP-1 medicines have become synonymous with weight loss, at least one expert thinks amylin would have been the go-to target if biopharma had been focused on the blockbuster indication 10 year…
  biospace · 13d ago
• Iambic CEO on taking an AI drug company public
  Fresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug development evolving.
  biopharma_dive · 15d ago